4-fluoro-2-(4-aminophenyl)benzothiazole | 328087-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-fluoro-2-(4-aminophenyl)benzothiazole
• 英文别名: 2-(4-aminophenyl)-4-fluorobenzothiazole；4-(4-fluorobenzo[d]thiazol-2-yl)aniline；4-(4-Fluoro-benzothiazol-2-yl)-phenylamine；4-(4-fluoro-1,3-benzothiazol-2-yl)aniline
• CAS: 328087-14-5
• 化学式: C₁₃H₉FN₂S
• 分子量: 244.292
• InChiKey: PIHNGKFWWSAHPY-UHFFFAOYSA-N

物化性质

• 熔点：
  219-221 °C
• 沸点：
  426.4±51.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-fluoro-2-(4-aminophenyl)benzothiazole 在 一氯化碘 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 生成 2-(4-amino-3-iodophenyl)-4-fluorobenzothiazole
  参考文献：
  名称：

  Substituted 2-arylbenzazole compounds and their use as antitumour agents

  摘要：

  公式（I）中X代表S或O，Q代表直接键，—CH2—或—CH═CH—的2-苯基苯并唑化合物表现出对哺乳动物肿瘤细胞的选择性抗增殖活性。在至少首选实施例中，苯并唑核的苯环具有卤素取代基，优选是氟，并且2-苯基团具有4'-氨基取代基，可能与氨基酸共轭以提供水溶性氨基酸酰胺前药或其盐。

  公开号：

  US06858633B1
• 作为产物：
  描述：

  N-(2-fluorophenyl)-4-nitrobenzamide 在 劳森试剂 、 六甲基磷酰三胺 、 sodium hydroxide 、 tin(ll) chloride 、 potassium hexacyanoferrate(III) 作用下， 以 乙醇 为溶剂， 反应 21.0h， 生成 4-fluoro-2-(4-aminophenyl)benzothiazole
  参考文献：
  名称：

  Antitumor Benzothiazoles. 14. Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles

  摘要：

  Synthetic routes to a series of mono- and difluorinated 2-(4-amino-3-substituted-phenyl)benzothiazoles have been devised. Whereas mixtures of regioisomeric 5- and 7-fluorobenzothiazoles were formed from the established Jacobsen cyclization of precursor 3-fluorothiobenzanilides, two modifications to this general process have allowed the synthesis of pure samples of these target compounds. Fluorinated 2-(4-aminophenyl)benzothiazoles were potently cytotoxic (GI(50) < 1 nM) in vitro in sensitive human breast MCF-7 (ER+) and MDA 468 (ER-) cell lines but inactive (GI(50) > 10 muM) against PC 3 prostate, nonmalignant HBL 100 breast, and HCT 116 colon cells. The biphasic dose-response relationship characteristically shown by the benzothiazole series against sensitive cell lines was exhibited by the 4- and 6-fluorobenzothiazoles (10b,d) but not by the 5- and 7-fluoro-benzothiazoles (10h,i). The most potent broad spectrum agent in the NCI cell panel was 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (10h) which, unlike the g-fluoro isomer (10d), produces no exportable metabolites in the presence of sensitive MCF-7 cells. Induction of cytochrome P450 CYP1A1, a crucial event in determining the antitumor specificity of this series of benzothiazoles, was not compromised. 10h is currently the focus of pharmaceutical and preclinical development.

  DOI：

  10.1021/jm001104n

文献信息

• 1-Phenyl-<i>N</i>-(benzothiazol-2-yl)methanimine derivatives as Middle East respiratory syndrome coronavirus inhibitors
  作者：Min-Qi Hu、Heng Li、Ying Lin、Ying Zhang、Jie Tang、Jian-Ping Zuo、Li-Fang Yu、Xian-Kun Tong、Wei Tang、Fan Yang

  DOI：10.1039/d0ra08442e

  日期：——

  A series of novel 1-phenyl-N-(benzothiazol-2-yl)methanimine derivatives were synthesized and their in vitro inhibitory potencies were evaluated on MERS-S pseudovirus.

  一系列新颖的1-苯基-N-(苯并噻唑-2-基)甲醛亚胺衍生物被合成，并在MERS-S假病毒上评估了它们的体外抑制效力。
• Substituted 2-arylbenzazole compounds and their use as antitumour agents
  申请人：Stevens Malcolm F. G.

  公开号：US06858633B1

  公开（公告）日：2005-02-22

  Substituted 2-phenylbenzazole compounds of formula (I) wherein X represents S or O and Q represents a direct bond, —CH2— or —CH═Ch—, exhibt selective antiproliferactive activity in respect of mammalian tumour cells. At least in preferred enbodiments the benzene ring of the benzazole nucleus has a halogen substituent, preferably flourine, and the 2-phenyl group has a 4′-amino substituent which may be conjugated with an amino acid to provide a water soluble amino acid amide prodrug or salt thereof.

  公式（I）中X代表S或O，Q代表直接键，—CH2—或—CH═CH—的2-苯基苯并唑化合物表现出对哺乳动物肿瘤细胞的选择性抗增殖活性。在至少首选实施例中，苯并唑核的苯环具有卤素取代基，优选是氟，并且2-苯基团具有4'-氨基取代基，可能与氨基酸共轭以提供水溶性氨基酸酰胺前药或其盐。
• 4-Substituted 4-Hydroxycyclohexa-2,5-dien-1-ones with Selective Activities against Colon and Renal Cancer Cell Lines
  作者：Geoffrey Wells、Jane M. Berry、Tracey D. Bradshaw、Angelika M. Burger、Angela Seaton、Bo Wang、Andrew D. Westwell、Malcolm F. G. Stevens

  DOI：10.1021/jm020984y

  日期：2003.2.1

  The synthesis and antitumor evaluation of a series of new heteroaromatic- and aromatic-substituted hydroxycyclohexadienones ("quinols"), and their imine counterparts, are described. The quinols were synthesized via the addition of a lithiated aromatic moiety to a quinone ketal followed by deprotection. When the aromatic portion of the molecule is a fused heterobicyclic structure (e.g., benzothiazole

  描述了一系列新的杂芳族和芳族取代的羟基环己二酮（“喹诺尔”）及其亚胺对应物的合成和抗肿瘤评价。通过将锂化的芳族部分添加至醌缩酮，然后脱保护来合成喹诺醇。当分子的芳族部分是稠合的异双环结构（例如，苯并噻唑衍生物7a）时，在HCT 116（GI50 = 40 nM）和HT 29（GI50 = 380 nM）人结肠中也观察到了强大的体外抗肿瘤活性。作为MCF-7和MDA 468人乳腺癌细胞系。在NCI发育治疗药物筛选计划的体外筛选（60种人类癌细胞系）上进行检查时，该系列化合物中的活性化合物始终显示出高度不同寻常的选择性模式；细胞毒性（LC50）仅集中在某些结肠和肾细胞系中。类似物7a还显示了在裸NMRI小鼠中针对人RXF 944XL肾异种移植物的体内抗肿瘤活性，并且是进一步研究的焦点。
• [EN] SUBSTITUTED 2-ARYLBENZAZOLE COMPOUNDS AND THEIR USE AS ANTITUMOUR AGENTS<br/>[FR] COMPOSES DE 2-ARYLBENZAZOLE SUBSTITUES ET LEUR UTILISATION COMME AGENTS ANTITUMORAUX
  申请人：CANCER RES CAMPAIGN TECH

  公开号：WO2001014354A1

  公开（公告）日：2001-03-01

  Substituted 2-phenylbenzazole compounds of formula (I) wherein X represents S or O and Q represents a direct bond, -CH2- or -CH=CH-, exhibit selective antiproliferative activity in respect of mammalian tumour cells. At least in preferred embodiments the benzene ring of the benzazole nucleus has a halogen substituent, preferably fluorine, and the 2-phenyl group has a 4'-amino substituent which may be conjugated with an amino acid to provide a water soluble amino acid amide prodrug or salt thereof.

  公式（I）中的2-苯基苯并咪唑化合物，其中X代表S或O，Q代表直接键，-CH2-或-CH=CH-，在哺乳动物肿瘤细胞中表现出选择性抗增殖活性。在至少优选实施例中，苯并咪唑核的苯环具有卤素取代基，优选为氟，而2-苯基基团具有4'-氨基取代基，可以与氨基酸结合以提供水溶性氨基酸酰胺前药或其盐。
• 4-Aryl quinols and analogs thereof as therapeutic agents
  申请人：——

  公开号：US20040220236A1

  公开（公告）日：2004-11-04

  The present invention pertains to compounds of the formula (I) which are, inter alia, antiprolilferative agents, anticancer agents, anitimycohacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitor: wherein: Q is ═O or ═N—S(═O) 2 —R Q ; R Q is -II or optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; Ar is optionally substituted C 5-20 aryl; R O is an oxy substituent; the bond marked &agr; is a single bond or a double bond; the bond marked &bgr; is a single bond or a double bond; R 3 and R 5 are each independently ring substituents; R 2 and R 6 are each independently ring substituents; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), mycobacterial infections (e.g., tuberculosis), and/or conditions mediated by thioredoxin/thioredoxin reductase. 1

  本发明涉及化合物的公式（I），其是抗增殖剂，抗癌剂，抗结核菌剂，抗结核病剂和/或硫氧还蛋白/硫氧还蛋白还原酶抑制剂，其中：Q是═O或═N-S（═O）2-RQ; RQ是-II或可选取代的C1-7烷基，C3-20杂环基或C5-20芳基; Ar是可选取代的C5-20芳基; RO是氧代取代基; 标记为&agr;的键是单键或双键; 标记为&bgr;的键是单键或双键; R3和R5各自独立地是环取代基; R2和R6各自独立地是环取代基; 以及其药学上可接受的盐，酯，酰胺，溶剂化合物，水合物和保护形式。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是体外还是体内，例如，用于治疗增殖性疾病（例如癌症），结核菌感染（例如结核病）和/或由硫氧还蛋白/硫氧还蛋白还原酶介导的疾病。